A NEW TOOL TO DEBRIDE INFECTED IMPLANTS

I tannhelsefeltet er orale biofilmer—kjent som plakk—årsak til alvorlige tannproblemer, inkludert tap av kjevebein, tenner og tannimplantater. Til tross for store fremskritt innen munnhygiene, er vi fortsatt sterkt avhengige av antibiotikabehandling for å håndtere problemer relatert til biofilm og lokale infeksjoner. Det norske selskapet Corticalis AS jobber for å revolusjonere dette feltet med patenterte produkter for antibiotika-fri behandling av biofilm-relaterte sykdommer i munnhulen. Corticalis anvender en banebrytende "biomimetisk" tilnærming, som etterligner biologiske prosesser for effektivt å takle problemet med akkumulering av biofilm og biofilm induserte lokale infeksjoner. Teknologien forhindrer og fjerner biofilm på en sikker, bærekraftig og miljøvennlig måte og tilbyr effektiv løsninger for profesjonell infeksjonskontroll rundt tenner og tannimplantater.

Corticalis AS has developed NuBone Gel - a novel and patented gel for the abolishment of oral biofilms that, in severe cases, induce bone degradation, tooth loss and dental implant failure and a brush, NuBone®Debrilator made out of titanium. Our product’s biomimetic mode of action and its multiple effects, both antibacterial and abrasive to enable debridement, allows for an ultra-effective, safe and predictable biofilm removal. Corticalis will lead the project, which will focus on product maturation, preparation of the market launch and commercialisation of our non-antibiotic-based product. The main barriers for Corticalis going forward are prevailing technical and market-related challenges. This project will enable performing the final optimisation on the packaging, preparing a pilot production to supply testing activities and clinical studies to reach the CE certification, demonstrating the product to end-users (dentists, hygienists, dental surgeons and patients), and preparing the market launch in Europe and US. This RCN program provides a unique opportunity for Corticalis to showcase the potential of our innovation and gain market intelligence. Completing the project objectives is important for ensuring a successful entrance to the market and commercialization of our innovative gel product. Our products will be a game changer in improving dental care, entering the peri-implant and periodontal disease treatment market, which has a business potential over 470M€/year in Europe. This project will put Corticalis in the frontline of dental care debridement, with the opportunity to generate accumulated revenues of 138M€ until 2030.